IPP Bureau
Alembic receives USFDA final approval for Ticagrelor Tablets, 90 mg and tentative approval for Ticagrelor Tablets, 60 mg
By IPP Bureau - May 03, 2025
Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,
USFDA inspection at Concord Biotech’s API facility at Dholka
By IPP Bureau - May 03, 2025
These observations are procedural in nature and none of them are related to data integrity
Vanta Bioscience receives GLP compliance re-certification
By IPP Bureau - May 03, 2025
This recertification of Company's OECD GLP is testimony to company's unwavering commitment to maintain international quality standards at the facility
Neuland Laboratories completes USFDA inspection at Unit 2
By IPP Bureau - May 03, 2025
The FDA issued Form 483 with one observation related to building and facility management
Sanofi Consumer Healthcare India Q1 PAT up 12.9%
By IPP Bureau - May 03, 2025
The Q1 2025 also witnessed a successful launch of Allegra D
Zydus receives final approval from USFDA for Niacin Extended-Release Tablets USP
By IPP Bureau - May 02, 2025
Niacin is indicated to reduce elevated total cholesterol, LDL cholesterol, apolipoprotein B and triglycerides (TG)
Vimta Labs posts Q4 FY25 PAT at Rs. 18.31 Cr
By IPP Bureau - May 01, 2025
Vimta Labs has reported total income of Rs. 96.08 crores during the period ended March 31, 2025
Sigachi Industries signs MoU with Respilon Group
By IPP Bureau - May 01, 2025
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
USFDA inspects Marksans’s subsidiary Time-Cap Laboratories' manufacturing facility
By IPP Bureau - May 01, 2025
The Subsidiary has received one inspectional observation in Form 483
Strides receives USFDA approval for anti-inflammatory Celecoxib Capsules
By IPP Bureau - May 01, 2025
Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base
CHMP recommends EU label update for Roche’s Phesgo to allow administration outside of clinical settings
By IPP Bureau - May 01, 2025
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
Briefs: Alembic Pharmaceuticals and Bafna Pharmaceuticals
By IPP Bureau - May 01, 2025
Alembic Pharmaceuticals commissions new facility at Pithampur
Dr. Morepen launches Rs. 499 annual multivitamin pack on Labour’s Day
By IPP Bureau - May 01, 2025
Priced at just Rs. 499 for 1-year supply, this initiative is aligned with the vision of Health for All
Aster DM Healthcare completes acquisition of 5% stake in Quality Care India
By IPP Bureau - May 01, 2025
The transaction structured as share swap, is valued at ~Rs. 849 crore, with no cash outflow
Gland Pharma receives USFDA approval for Latanoprostene Bunod Ophthalmic Solution
By IPP Bureau - May 01, 2025
This Product is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension
